Logo image of DRTS

ALPHA TAU MEDICAL LTD (DRTS) Stock Fundamental Analysis

USA - NASDAQ:DRTS - IL0011839383 - Common Stock

4.09 USD
+0.28 (+7.35%)
Last: 9/19/2025, 8:00:01 PM
4.1 USD
+0.01 (+0.24%)
After Hours: 9/19/2025, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, DRTS scores 2 out of 10 in our fundamental rating. DRTS was compared to 191 industry peers in the Health Care Equipment & Supplies industry. DRTS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DRTS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

DRTS had negative earnings in the past year.
In the past year DRTS has reported a negative cash flow from operations.
In the past 5 years DRTS always reported negative net income.
In the past 5 years DRTS always reported negative operating cash flow.
DRTS Yearly Net Income VS EBIT VS OCF VS FCFDRTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -31.73%, DRTS is in line with its industry, outperforming 41.88% of the companies in the same industry.
DRTS has a Return On Equity (-40.64%) which is in line with its industry peers.
Industry RankSector Rank
ROA -31.73%
ROE -40.64%
ROIC N/A
ROA(3y)-30.7%
ROA(5y)-34.69%
ROE(3y)-39.04%
ROE(5y)-55.73%
ROIC(3y)N/A
ROIC(5y)N/A
DRTS Yearly ROA, ROE, ROICDRTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

DRTS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DRTS Yearly Profit, Operating, Gross MarginsDRTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for DRTS has been increased compared to 1 year ago.
Compared to 5 years ago, DRTS has more shares outstanding
DRTS has a worse debt/assets ratio than last year.
DRTS Yearly Shares OutstandingDRTS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
DRTS Yearly Total Debt VS Total AssetsDRTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

DRTS has an Altman-Z score of 5.61. This indicates that DRTS is financially healthy and has little risk of bankruptcy at the moment.
DRTS has a better Altman-Z score (5.61) than 82.72% of its industry peers.
DRTS has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.07, DRTS is in the better half of the industry, outperforming 65.44% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 5.61
ROIC/WACCN/A
WACCN/A
DRTS Yearly LT Debt VS Equity VS FCFDRTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 10.52 indicates that DRTS has no problem at all paying its short term obligations.
DRTS has a better Current ratio (10.52) than 94.24% of its industry peers.
DRTS has a Quick Ratio of 10.52. This indicates that DRTS is financially healthy and has no problem in meeting its short term obligations.
DRTS's Quick ratio of 10.52 is amongst the best of the industry. DRTS outperforms 94.76% of its industry peers.
Industry RankSector Rank
Current Ratio 10.52
Quick Ratio 10.52
DRTS Yearly Current Assets VS Current LiabilitesDRTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

DRTS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.00%.
EPS 1Y (TTM)-20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, DRTS will show a very strong growth in Earnings Per Share. The EPS will grow by 25.30% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-10.77%
EPS Next 2Y8.53%
EPS Next 3Y40.43%
EPS Next 5Y25.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DRTS Yearly Revenue VS EstimatesDRTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
DRTS Yearly EPS VS EstimatesDRTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DRTS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRTS Price Earnings VS Forward Price EarningsDRTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRTS Per share dataDRTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as DRTS's earnings are expected to grow with 40.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.53%
EPS Next 3Y40.43%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DRTS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALPHA TAU MEDICAL LTD

NASDAQ:DRTS (9/19/2025, 8:00:01 PM)

After market: 4.1 +0.01 (+0.24%)

4.09

+0.28 (+7.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)N/A N/A
Inst Owners1.78%
Inst Owner Change8.06%
Ins Owners16.26%
Ins Owner ChangeN/A
Market Cap347.81M
Analysts86
Price Target8.67 (111.98%)
Short Float %0.16%
Short Ratio1.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2%
Min EPS beat(2)-11.55%
Max EPS beat(2)7.55%
EPS beat(4)2
Avg EPS beat(4)2.35%
Min EPS beat(4)-11.55%
Max EPS beat(4)18.47%
EPS beat(8)6
Avg EPS beat(8)11.12%
EPS beat(12)9
Avg EPS beat(12)17.76%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.86%
PT rev (3m)-2.86%
EPS NQ rev (1m)0.22%
EPS NQ rev (3m)-1.99%
EPS NY rev (1m)-3.86%
EPS NY rev (3m)0.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.02
P/tB 4.02
EV/EBITDA N/A
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0
BVpS1.02
TBVpS1.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.73%
ROE -40.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.7%
ROA(5y)-34.69%
ROE(3y)-39.04%
ROE(5y)-55.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 495.91%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.52
Quick Ratio 10.52
Altman-Z 5.61
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)296.97%
Cap/Depr(5y)1091.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
EPS Next Y-10.77%
EPS Next 2Y8.53%
EPS Next 3Y40.43%
EPS Next 5Y25.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.78%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-39.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.9%
OCF growth 3YN/A
OCF growth 5YN/A